Is the acromegalic cardiomyopathy reversible? Effect of 5-year normalization of growth hormone and insulin-like growth factor I levels on cardiac performance

Journal of Clinical Endocrinology and Metabolism

Volumn 86, Issue 4, 2001, Pages 1551-1557

  Colao, Annamaria ^a   Cuocolo, Alberto ^a,b   Marzullo, Paolo ^a   Nicolai, Emanuele ^a   Ferone, Diego ^a   Della Morte, Anna Maria ^a   Pivonello, Rosario ^a,b   Salvatore, Marco ^a   Lombardi, Gaetano ^a  

^a UNIVERSITY OF NAPLES FEDERICO II   (Italy)

^b IRCCS NEUROMED   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

GROWTH HORMONE; OCTREOTIDE; SOMATOMEDIN C;

ACROMEGALY; ADULT; ARTICLE; CARDIOMYOPATHY; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE CONTROL; EXERCISE; FEMALE; HEART LEFT VENTRICLE EJECTION FRACTION; HEART PERFORMANCE; HEART RATE; HUMAN; MALE; PRIORITY JOURNAL; SCINTIANGIOGRAPHY; WORKLOAD;

ACROMEGALY; ADULT; CARDIOMYOPATHIES; EXERCISE; FEMALE; HEART; HORMONES; HUMAN GROWTH HORMONE; HUMANS; INSULIN-LIKE GROWTH FACTOR I; MALE; MIDDLE AGED; OCTREOTIDE; PHYSICAL ENDURANCE; PROSPECTIVE STUDIES; RADIONUCLIDE ANGIOGRAPHY; STROKE VOLUME; TIME FACTORS;

EID: 0035040518     PISSN: 0021972X     EISSN: None     Source Type: Journal    
DOI: 10.1210/jc.86.4.1551     Document Type: Article

References (48)

1. Acromegaly
2. Epidemiology and long term survival in acromegaly
3. An audit of outcome of treatment in acromegaly
4. Determinants of clinical outcome and survival in acromegaly
5. Mortality in acromegaly
6. Mortality and cancer incidence in acromegaly: A retrospective cohort study
7. Growth hormone and the heart
8. Is growth hormone bad for your heart: Cardiovascular impact of GH deficiency and excess
9. Acromegaly
10. Echocardiographic evidence for a direct effect of GH/IGF-I hypersecretion on cardiac mass and function in young acromegalics
11. Cardiovascular effects of short-term growth hormone hypersecretion
12. Impaired left ventricular diastolic function in acromegaly: An echocardiographic study
13. Subclinical cardiac dysfunction in acromegaly: Evidence for a specific disease of heart muscle
14. Acromegalic cardiopathy: A left ventricular scintigraphic study
15. Impaired left ventricular diastolic filling in patients with acromegaly: Assessment with radionuclide angiography
16. Impact of patient's age and disease duration on cardiac performance in acromegaly: A radionuclide angiography study
17. Systemic hypertension and impaired glucose tolerance are independently correlated to the severity of the acromegalic cardiomyopathy
18. Cardiac effect of thyrotoxicosis in acromegaly
19. Cardiac involvement in acromegaly: Specific myocardiopathy or consequence of systemic hypertension
20. The cardiovascular effects of octreotide treatment in acromegaly: An echocardiographic study
21. Chronic treatment with the somatostatin analog octreotide improves cardiac abnormalities in acromegaly
22. Effects of octreotide on left ventricular mass in acromegaly
23. Rapid reduction of left ventricular hypertrophy in acromegaly after suppression of growth hormone hypersecretion
24. Cardiac effects of lanreotide, a slow release somatostafin analog, in acromegalic patients
25. Regression of acromegalic left ventricular hypertrophy after lanreotide (a slow release somatostatin analog)
26. Cardiovascular aspects in acromegaly: Effects of treatment
27. Cardiovascular effects of the somatostatin analog octreotide in acromegaly
28. Effects of one-year treatment with octreotide on cardiac performance in patients with acromegaly
29. Growth-hormone and prolactin excess
30. Criteria for cure of acromegaly: A consensus statement
31. Hypertension control. Report of a WHO expert committee
32. Prediction of efficacy of octreotide therapy in patients with acromegaly
33. Effect of octreotide pretreatment on surgical outcome in acromegaly
34. Impaired left ventricular diastolic filling in patients with coronary artery disease: Assessment with radionuclide angiography
35. Left ventricular peak ejection rate, filling rate and ejection fraction: Frame requirements at rest and exercise
36. Left ventricular hypertrophy and impaired diastolic filling in essential hypertension
37. Effects of valsartan on left ventricular diastolic function in patients with mild or moderate essential hypertension: Comparison with enalapril
38. Anatomie pathologique, lesions et trouble cardiovasculaires de l'acromegalie
39. Long-term mortality after transsphenoidal surgery and adjunctive therapy for acromegaly
40. Long-term endocrinological follow-up evaluation in 115 patients who underwent transsphenoidal surgery for acromegaly
41. Consensus statement: Benefits versus risks of medical therapy for acromegaly
42. Octreotide
43. Direct demonstration of insulin-like growth factor I induced nitric oxide production by endothelial cells
44. Nitric oxide mediates the hemodynamic effects of recombinant growth hormone in patients with acquired growth hormone deficiency
45. Short term reduction of left ventricular mass in primary hypertrophic cardiomyopathy by octreotide injections
46. Effects of octreotide in patients with hypertrophic obstructive cardiomyopathy
47. Localisation and quantitation of autonomic innervation in the porcine heart I: Conduction system